6 Sites on 1500 SubjectsCardiovascular & MetabolicPHASE IV
ESMERALDA: Metformine in tha treatment of patients with abnormal GTT with overweigth or obesity. AVENTIS 2009
Protocol Design
Start-up
Regulatory Affairs
Clinical Operations
10 Sites on 138 SubjectsCardiovascularPHASE III
Aliskiren. Phase III trials to assess the long time period of efficacy of this molecule as antihypertensive medication. NOVARTIS 2008
Start-up
Regulatory Affairs
10 Sites on 300 SubjectsCardiovascularPHASE III
Valsartan. Phase III Triasl to assess the efficacy and safety of valsartan alone and in combination with hydroclorothiazide with or amlodipine for aterial hypertension control. NOVARTIS 2005-2008
CARMELA: Cardiovascular Risk factors Multiple Evaluation in Latin Americans. Pfizer 2004-2005
Sample Design
Control of all epidemiological processes
Regulatory Affairs
Clinical Operations
10 Sites on 300 SubjectsCardiovascularPHASE III
Valsartan. Phase III Triasl to assess the efficacy and safety of valsartan alone and in combination with hydroclorothiazide with or amlodipine for aterial hypertension control. NOVARTIS 2005-2008
Start-up
Regulatory Affairs
Clinical Operations
1 Sites and 24 subjectsCardiovascularPHASE III
Navigator: (CDJN608B2302) Trial that assess the prevention of diabetes and cardiovascular outcomes with the intervention of two drugs (Nateglinide and Valsartan) NOVARTIS 2002-2006
Start-up
Regulatory Affairs
Clinical Operations
10 Sites and 300 subjectsCardiovascular & MetabolismEpidemiological
Atorvastatin in high level of cholesterol and dyslipidemia. An epidemiological and clinical trial. PFIZER 1998-1999
Start-up
Regulatory Affairs
Clinical Operations
1 Sites and 150 subjectsCardiovascular & MetabolismPhase IV
Fluvastin in hypercholeterolaemic and dislipidemic patients. NOVARTIS 1997-1999
Start-up
Regulatory Affairs
Clinical Operations
2 Sites and 80 subjectsCardiovascular Phase III
Benazepril in systemic arterialhypertension.Phase III CIBA GEIGY 1988-1990